Page 22 - Sohini Das

DRL trims workforce costs by 25% amid Revlimid-linked margin strain

There are 21,757 permanent employees on company rolls as on March 31, 2024; cost optimisation to offset margin pressure due to declining Revlimid sales

Sun Pharma stock up 2.15% as US court clears alopecia drug launch

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 million in FY27

Luxury car sales hit record in FY25; FY26 outlook remains cautious

The overall luxury car market had grown by around 3 per cent in FY25

US tops India's pharma exports with $9.8 bn share in April-Feb FY25

Despite looming tariffs, shipments to US grew 14%; EU and Africa next on the pharma export map

Chetak top-selling electric two-wheeler in Q4FY25, says Bajaj Auto

The Chetak was originally introduced in the 1970s, when it had a strong presence in the Indian scooter market for several decades

JLR's North America wholesale volumes up in Q4 ahead of Trump's tariffs

JLR posts flat volume growth for FY25

Metropolis Healthcare expands footprint in North with Dapic acquisition

With its third acquisition in recent times, Metropolis' Ameera Shah said the firm will make another deal this financial year

US buyers rethink India orders as Trump's reciprocal tariff woes bite

Buyers are reassessing existing orders, with some seeking discounts. They are also exploring the best possible sources for imports, given the varied but steep reciprocal tariffs, exporters said

India should expedite efforts to become full ICH member: ISCR president

Policymakers should establish dedicated clinical research units within premier institutions like Aiims and NIPERs, regulatory authorities too would need support in developing their domain expertise

Tata Motors' arm Jaguar Land Rover may look to clear US inventory fast

Analysts feel company will focus on profitable growth besides volume growth JLR likely to have 1-2 months' inventory in US which will now liquidate faster

Pharma companies likely to pass on costs in US as fresh levy looms

Brokerages also felt that the pharma companies will aim to pass on the tariff hike to payors

Short-term painkiller? Pharma Inc gets a breather from US tariffs

Tariff worries, raw material costs still ail sector

Drug prices may rise in US if Indian pharma firms pass on Trump's tariff

The US administration has not made announcements yet on sector-specific tariffs

Fortis Healthcare secures rights to Fortis brand in public auction

Wins bid for Rs 200 crore at December auction to acquire trademark

'Scenario building' in Indian Pharma Inc ahead of US tariff announcement

Pharma products have been on the radar of US President Donald Trump, who has indicated that tariffs of up to 25 per cent could be imposed on this sector

Agilus Diagnostics lowers marketing spend 2 years after rebranding

In FY25, an additional Rs 50 crore was spent on marketing over and above the usual budget

Auto street set for rough ride as Donald Trump tariffs spark worries

India calculating impact of 25% duty on cars, auto parts; firms see hit on margins

Manufacturing sector must not rely on tariffs for cover: India Inc

With supply chain uncertainties looming, companies are trying to procure more components and create an inventory, felt industry insiders

M&M in talks to acquire Sumitomo Corporation's stake in SML Isuzu

Sumitomo holds 44% in SML Isuzu; current stake valued at Rs 1,100 cr; deal may happen at a discount to current trading price

Used-car sales likely to outpace new ones in FY26 as demand surges

Secondhand-car market seeing strong growth in Bengaluru, Hyderabad, Pune